Skip to content
Building resilience in biopharma

The global biopharmaceutical market is estimated at $ 330.7 billion in 2021 and is expected to reach $ 478.08 billion by 2026. Despite promising growth projections, the pandemic has become a reality for the industry, leaving leaders think about ways to build an ecosystem capable of dealing with such an unprecedented situation in the future. With a renewed sense of purpose, the industry is betting high on technology to embrace newer and advanced methods of drug development and bring resilience to the sector as a whole.

To discuss the industry’s paradigm shift, thought leaders from the biopharmaceutical sector gathered in a series of interesting panel discussions presented by CNBC-TV18 in collaboration with Cytiva. Moderated by Archana Shukla, Associate Editor-in-Chief, Pharma & Healthcare and Office Manager, CNBC-TV18, each of the sessions brought together prominent industry leaders who shared their perspectives on the disruption of the industry and the how innovation and technology are at the heart of the undergoing transformation.

The first session had an engaging discussion on ‘Building Resilience in Biopharma Manufacturing’, Dr Sanjay Singh, CEO of Gennova, spoke about the challenges that the pandemic has brought to the entire biopharma community and how whose industry is using new platforms to solve the problem. Raghavendra Goud Vaggu, GM Biopharma, Southeast Asia, Cytiva, also spoke about how adoption of the technology can boost the manufacturing agility of the biopharmaceutical industry and how Cytiva has contributed to the same through its heritage of providing innovative solutions to industry.

Dr Mahesh Bhalgat, COO of Syngene Intl Ltd highlighted how AI and machine learning capabilities have been used in the industry. Commenting on how emerging technologies are transforming the industry, he said, “With improved speed as well as data visualization and processing, an analyst can now analyze data in near real-time, helping the industry innovate and improve. thrive in recent months. “

Regulators, too, have improved their position and allow innovations to flourish. According to Sriram Shrinivasan, partner and global leader in emerging markets, EY, regulators are now working with industry to change their role from earlier gatekeepers to currently facilitators, adding that this is a very good sign for the industry.

Dr Manish Diwan, GM & HoD, SPED, BIRAC – PSU of DBT said: “Biopharma has been one of the fastest growing industries over the past five years. . The industry has recorded a compound annual growth of almost 55% during this period and is expected to grow another 22% in a few years. “

Speaking about the current focus on biosimilars in industry, the role of biologics and biopharmaceuticals in respecting the disease burden and population of the country and the need to focus on innovative molecules in India, Dr Himanshu Gadgil said: “Biosimilars had a role to play in increasing access as well as affordability of these life-saving treatments which otherwise would have remained inaccessible to the majority of the Indian population and in so doing, the biosimilars industry has put in place all the know-how necessary to bring these complex molecules to patients. “

The panelists also discussed various aspects of building an innovation ecosystem in the industry. Referring to a study conducted by Cytiva with 1,100 executives in 20 key countries to understanding the biopharmaceutical resilience of each country, Dr Firman Ghouze, Marketing Director – Asia Pacific, Cytiva spoke about the index measured across five pillars. keys to the resilience of the supply chain, talent pool, R&D ecosystem, manufacturing agility and government policies and regulations, and talent scouting is a key bottleneck in the industry at present.

Highlighting the long time it takes to convert basic research into a product, Professor KJ Mukherjee, Biochemical Engineering and Biotechnology, IIT Delhi felt that the country has excellent research, that an ecosystem is needed that facilitates seamless entry on the market to drive innovation in the sector.

Examining how India is positioning itself and what remains to be done to make the country the biopharmaceutical capital of the world, the following session titled “Making India the Biologics Capital of the World” highlighted the issues and how India could become the world leader in organic products by closing the gap.

Discussing the development progress of Biopharmaceuticals India, Dr Rakesh Mishra, Director of the Tata Institute For Genetics, presented areas where the Indian biopharmaceutical industry needs to be improved.

Accepting the renewed focus on innovation in the biopharmaceutical sector, which occupies a central place in the current healthcare ecosystem, the panelists analyzed the support required and the need to harmonize the ecosystem under one digital roof. Centralization, as discussed, will contribute to faster access of drugs to patients.

Dr Sundar Ramanan, Senior Vice President, Strategic Biotherapeutics Operations, Just-Evotec Biologics, mentioned that we need to move from the concept of ‘cheap equipment and labor’ to that of ‘labor. skilled work and robotics’ to achieve the scale necessary to be the market leader in the field of biotechnology. Francis Van Parys, Vice President, Commercial, Asia-Pacific, Cytiva, also reiterated the importance of adopting technology to improve productivity and efficiency, which can enable manufacturing infrastructure to l India to progress in leaps and bounds in addition to the great work that the country is already doing. .

Looking at the challenges facing Indian biopharmacy today regarding the differences in the regulation of clinical trials between India and other regulated markets, the panelists agreed on the harmonization of the drug regime. clinical trials as a solution to the problem. The panel also discussed ways to attract investment and funding to the sector.

The captivating series of discussions offered an intuitive perspective on how India can become the undisputed biopharmaceutical champion of the world in the years to come. Emphasizing the potential as well as the obstacles in the path of industry growth, each session provided a deep dive into the industry. If you missed watching the series, you can follow the full conversation here.

This is a partnership post.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.